show

AbbVie presents an in-depth look at our research and development pipeline for investors on June 3, 2016. This site provides information from the event, including complete presentation materials and additional resources on Oncology, Immunology, Neuroscience and Virology.

AbbVie R&D Day 2016

AbbVie’s late-stage pipeline has the potential to deliver more than 20 new medicines or indications by 2020. For more details on our growth strategy view the full AbbVie R&D Day presentation and webcast, agenda, videos, speaker bios and more.

AbbVie R&D Day 2016 - Oncology

AbbVie’s growing strengths in oncology include development expertise…

More

AbbVie R&D Day 2016 - Immunology

AbbVie continues its immunology leadership with a focus on developing next…

More

AbbVie R&D Day 2016 - Neuroscience

AbbVie is capitalizing on emerging biology and new technologies to expand…

More

AbbVie R&D Day 2016 - Virology

AbbVie is pursuing new regimens to advance the hepatitis C (HCV) treatment…

More

Media:

Adelle Infante
adelle.infante@abbvie.com

Investor Relations:

Liz Shea
liz.shea@abbvie.com

Embedly